AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3350994
Drug: Intravenous Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Prednisolone (IV PL) 10-mg
Trial: 28548898
Drug: Rapid albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid albuterol pathway with a breath-enhanced nebulizer (up to 4 treatments)
Trial: 28548898
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment arm (up to 2 continuous albuterol nebulizations)
Trial: 22945731
Drug: Irrigation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation with a hydroalcoholic solution of propolis extract twice a week for 2 weeks (group A)
Trial: 22945731
Drug: Irrigation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation with a placebo twice a week for 2 weeks (group B)
Trial: 22945731
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (group C)
Trial: 20490472
Drug: Blonanserin 2
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin 2 mg oral dose, administered under different conditions: fasting, 30 min before meal, 30 min after meal, 2 h after meal, 4 h after meal.
Trial: 26334929
Drug: STRIDE lifestyle
RxNorm normalized name: Stridex
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRIDE lifestyle intervention (weekly group meetings for 6 months, then monthly for 6 months)
Trial: 21198745
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (patients on dopamine agonist therapy)
Trial: 19101780
Drug: Olmesartan (RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (RAS inhibitor)
Trial: 19101780
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs without RAS inhibitors
Trial: 3370020
Drug: 9-week program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-week program of submaximal aerobic exercise three times weekly
Trial: 25084971
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (first-line antibiotics for 3 days)
Trial: 25084971
Drug: No Antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Antibiotic group
Trial: 22345687
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg initially, increasing to 4 mg after 8 weeks if necessary)
Trial: 22345687
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 and 4 mg)
Trial: 22157744
Drug: Ultrasound-guided interfascial
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided interfascial injection of 5 mL of lidocaine 2%
Trial: 22157744
Drug: Nerve stimulation-assisted
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulation-assisted technique with 5 mL of lidocaine 2%
Trial: 20501476
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered pre-sheath (before catheterization laboratory arrival)
Trial: 20501476
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered in-lab (after catheterization laboratory arrival)
Trial: 17711924
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen (17beta-estradiol) at doses of 0.5, 1, and 2 mg for 2 weeks each
Trial: 17711924
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (TD) at doses of 0.025, 0.0375, and 0.05 mg for 2 weeks each
Trial: 16334438
Drug: L-NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (4 mg kg-1 h-1)
Trial: 2478015
Drug: ATIII/heparin regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATIII/heparin regimen (1,500 units preoperatively and 1,000 units daily for five days)
Trial: 2478015
Drug: ATIII (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATIII (same dose as hip replacement)
Trial: 2478015
Drug: ATIII (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATIII (twice the dose used for hip replacement)
Trial: 2478015
Drug: ATIII/heparin, warfarin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATIII/heparin, warfarin, or dextran
Trial: 1266558
Drug: DHB 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHB 0.2 mg/kg
Trial: 1266558
Drug: Pentobarbital 2
RxNorm normalized name: pentobarbital 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital 2 mg/kg
Trial: 1266558
Drug: Halothane with
RxNorm normalized name: Halothane
DrugBank: Halothane (DB01159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halothane with pentobarbital 2 mg/kg
Trial: 31035902
Drug: Control (nonstatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nonstatin treatment)
Trial: 26711466
Drug: Mouthwash and
RxNorm normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash and a moisturizing gel (M + m)
Trial: 26711466
Drug: Water and
RxNorm normalized name: ALCOHOL 71 mL in 100 mL TOPICAL GEL [Anti Bacterial Hand Gel Rose Water and Ivy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water and a moisturizing gel (W + m)
Trial: 27099884
Drug: Ongoing GDMT
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing GDMT plus carotid baroreflex activation therapy (BAT) for 6 months
Trial: 23484763
Drug: Bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepotastine besilate ophthalmic solution (BBOS) 1.5%
Trial: 18271228
Drug: Estazolam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam (oral administration)
Trial: 15780846
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Delta‐9‐THC
Trial: 16988594
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CBD
Trial: 16988594
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg CBD
Trial: 11035338
Drug: Standard corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard corticosteroid dosage regimen for promotion of fetal lung maturation
Trial: 11035338
Drug: High-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroid regimen of >24 mg/d (10 mg dexamethasone IV every 6 hours for 2 doses followed by 6 mg IV every 6 hours for 2 to 4 doses)
Trial: 9447770
Drug: Colgate 0-6
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate 0-6 gel (400 ppm F)
Trial: 30403954
Drug: Ceftriaxone 500
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 500 mg
Trial: 29146890
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea ointment 3%
Trial: 27107670
Drug: Benzodiazepine dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine dosage reduction
Trial: 22908105
Drug: Moving to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moving to Opportunity (MTO) treatment (voucher for lower-poverty neighborhoods)
Trial: 16293412
Drug: Dydrogesterone 40
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 40 mg stat dose followed by 10 mg twice a day for one week
Trial: 7502999
Drug: Plasma selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma selenium levels in cases with MI (mean 114.4 ± 15.1 ng/g)
Trial: 7502999
Drug: Plasma selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma selenium levels in controls (mean 113.2 ± 15.7 ng/g)
Trial: 2102136
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg b.i.d.
Trial: 2935497
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg b.i.d.
Trial: 2102136
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg b.i.d. and 40 mg b.i.d.
Trial: 86158
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% adenine arabinoside 5'-monophosphate
Trial: 22331175
Drug: Melatonin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (4 mg)
Trial: 26153671
Drug: Infant-daily nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infant-daily nevirapine
Trial: 19695526
Drug: Microcurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent therapy (30 minutes) followed by stretching exercises (2 minutes); 3 treatments per week for 2 weeks.
Trial: 19695526
Drug: Stretching exercises
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching exercises after ultrasound therapy (30 minutes); 3 treatments per week for 2 weeks.
Trial: 12764910
Drug: Shengmai Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai Injection (SMI) plus conventional treatment of western medicine
Trial: 1917174
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment (two 10 mg/24 hour patches twice daily, at 8 a.m. and 8 p.m.)
Trial: 1917174
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (two 10 mg/24 hour patches at 8 a.m. and two placebo patches at 8 p.m.)
Trial: 1917174
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two placebo patches twice daily, at 8 a.m. and 8 p.m.)
Trial: 19664956
Drug: Standard topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard topical 4% lidocaine cream and injection of [(99m)Tc]Tc‐sulfur colloid (n=35)
Trial: 19664956
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo cream and injection of Tc‐sulfur colloid containing sodium bicarbonate (n=35)
Trial: 19664956
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo cream and injection of Tc‐sulfur colloid containing 1% lidocaine (n=35)
Trial: 19664956
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo cream and injection of Tc‐sulfur colloid containing sodium bicarbonate and 1% lidocaine (n=35)
Trial: 16398423
Drug: Xiaoshui Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoshui Decoction (XSD) combined with chemotherapy (DDP via abdominal infusion)
Trial: 16398423
Drug: DDP infusion
RxNorm normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP infusion alone (control group)
Trial: 12526189
Drug: Selective estrogen
RxNorm normalized name: Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen receptor modulators (SERMs)
Trial: 9690723
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg t.d.s.)
Trial: 9690723
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate (TDB) (120 mg q.d.s.)
Trial: 8620674
Drug: Zileuton 800mg
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton 800mg twice daily
Trial: 2703967
Drug: Methocarbamol 2.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methocarbamol 2.25, 4.5, and 9 g
Trial: 2703967
Drug: Lorazepam 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1, 2, and 4 mg
Trial: 22982605
Drug: d‐amphetamine (20mg-oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (20mg-oral)
Trial: 22982605
Drug: haloperidol (2mg-oral)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: haloperidol (2mg-oral)
Trial: 16935686
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 100 mug twice daily
Trial: 16935686
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 100 mug twice daily (open-label added if symptoms not controlled)
Trial: 12813384
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g bolus before incision, 200 mg/hour infusion during surgery)
Trial: 8707761
Drug: Adjunctive cytokine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive cytokine and progenitor cell support of hematologic recovery after myelosuppressive therapy
Trial: 1511228
Drug: Clonidine or
RxNorm normalized name: clonidine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine or guanfacine treatment
Trial: 28994675
Drug: Dexmedetomidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 μg/kg/h continuous infusion
Trial: 28994675
Drug: Dopamine 3
RxNorm normalized name: DOPamine 3.2 mg/mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine 3 μg/kg/min continuous infusion
Trial: 22802974
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg rSh28GST with aluminium hydroxide (Alum) as adjuvant (n=8)
Trial: 22802974
Drug: 300 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 µg rSh28GST (n=8)
Trial: 19006541
Drug: Ranitidine effervescent
RxNorm normalized name: ranitidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine effervescent tablets 75 mg (on-demand)
Trial: 19006541
Drug: Lansoprazole capsules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole capsules 15 mg (on-demand)
Trial: 17768579
Drug: Amiodarone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (600 mg/day to 900 mg/day intravenously on the first postoperative day, followed by 400 mg/day orally until hospital discharge or until completing seven days)
Trial: 11350207
Drug: D-tagatose (3x15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-tagatose (3x15 g daily)
Trial: 11350207
Drug: Placebo (sucrose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sucrose, 3x15 g daily)
Trial: 25400667
Drug: Royal Jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Jelly (RJ) applied three times per day during treatment
Trial: 23299850
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of PRP (Group A)
Trial: 23299850
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of PRP (Group B)
Trial: 20225605
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy considerations
Trial: 10867980
Drug: Clonidine hydrochloride
RxNorm normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine hydrochloride 0.2 mg
Trial: 10867980
Drug: Yohimbine hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine hydrochloride 22 mg
Trial: 10867980
Drug: Clonidine hydrochloride
RxNorm normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine hydrochloride 0.2 mg + Yohimbine hydrochloride 22 mg
Trial: 1590547
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg dose of ethanol
Trial: 1590547
Drug: Placebo dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose
Trial: 28295934
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (IDeg) 0.4 U/kg once daily
Trial: 22594461
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (IGlar) 0.4 U/kg once daily
Trial: 20538838
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg
Trial: 20538838
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg (healthy control)
Trial: 16521032
Drug: Cocaine infusions
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine infusions (0, 8, 16, and 32 mg/70 kg)
Trial: 16521032
Drug: Cocaine infusions
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine infusions (16 mg)
Trial: 12724276
Drug: VCY2 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCY2 antibody
Trial: 9505982
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg hydrocodone bitartrate with 400 mg ibuprofen
Trial: 3516291
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of apomorphine
Trial: 3516291
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of apomorphine
Trial: 29456025
Drug: Control (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (weekly e-mail newsletter)
Trial: 24812891
Drug: Kuanxiong Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuanxiong Aerosol (KA), sublingual spray 0.6 mL three times during angina attack
Trial: 24812891
Drug: Nitroglycerin Tablet
RxNorm normalized name: nitroglycerin Sublingual Tablet
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin Tablet (NT), 0.5 mg sublingually dissolved during angina attack
Trial: 24812891
Drug: Nitroglycerin Tablet
RxNorm normalized name: nitroglycerin Sublingual Tablet
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin Tablet (NT)
Trial: 23654012
Drug: Medicamentous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicamentous therapy (Diklofenak 100 mg, 2 tablets per day)
Trial: 18797179
Drug: AIC immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIC immunotherapy (6 escalating doses of AIC 0.06-12 microg; n = 12)
Trial: 8635184
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of tolcapone
Trial: 8635184
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of tolcapone
Trial: 2169213
Drug: 150 IU.kg‐1.day‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU.kg‐1.day‐1 heparin (group HEP)
Trial: 2169213
Drug: 1.2 mg.kg‐1.day‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg.kg‐1.day‐1 enoxaparin (group ENX)
Trial: 2169213
Drug: 0.8 mg.kg‐1.day‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg.kg‐1.day‐1 enoxaparin with 5 ng.kg‐1.min‐1 prostaglandin I2 (group ENX and PGI2)
Trial: 27444991
Drug: Continuous saline
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous saline bladder irrigation (CSBI) at 2000 mL/h for the first 1 hour, then 1000 mL/h for 2 hours, followed by 500 mL/h for 15 hours
Trial: 25976647
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 20 mg per day lutein (L), 0.86 mg per day zeaxanthin (Z); Ultra Lutein
Trial: 25976647
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 10 mg per day meso-zeaxanthin (MZ), 10 mg per day L, 2 mg per day Z; Macushield; Macuhealth
Trial: 25976647
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: 17 mg per day MZ, 3 mg per day L, 2 mg per day Z
Trial: 17083064
Drug: Enalapril (520
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (520 mg/d)
Trial: 10977396
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with the 23‐valent pneumococcal polysaccharide vaccine